Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.48 |
| ▸ | TOP1 | P11387 | 3/20 | 0.43 |
| ▸ | CYCS | P99999 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
| ▸ | TERT | O14746 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12392075 | 1.00 | ABCG2 (0.48) | ABCG2TOP1CYCSMAPTSMN1; SMN2 | |
| SCHEMBL17688986 | 1.00 | ABCG2 (0.48) | ABCG2TOP1CYCSMAPTSMN1; SMN2 | |
| SCHEMBL17688989 | 0.98 | ABCG2 (0.50) | ABCG2TOP1CYCSMAPTSMN1; SMN2 | |
| SCHEMBL12450828 | 0.98 | ABCG2 (0.45) | ABCG2TOP1CYCSMAPTSMN1; SMN2 | |
| SCHEMBL12392100 | 0.98 | ABCG2 (0.45) | ABCG2TOP1CYCSMAPTSMN1; SMN2 | |
| SCHEMBL24689574 | 0.98 | ABCG2 (0.50) | ABCG2TOP1CYCSMAPTSMN1; SMN2 | |
| SCHEMBL17688987 | 0.97 | ABCG2 (0.46) | ABCG2TOP1CYCSMAPTSMN1; SMN2 | |
| SCHEMBL17689321 | 0.97 | ABCG2 (0.46) | ABCG2TOP1CYCSMAPTSMN1; SMN2 | |
| SCHEMBL12451489 | 0.96 | ABCG2 (0.52) | ABCG2TOP1CYCSMAPTSMN1; SMN2 | |
| SCHEMBL12392069 | 0.96 | ABCG2 (0.52) | ABCG2TOP1CYCSMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3459955-B1 | NOVEL METHOD AND APPLICATION OF UNSYMMETRICALLY MESO-SUBSTITUTED PORPHYRINS AND CHLORINS FOR PDT | BIOLITEC UNTERNEHMENSBERATUNGS II AG (AT) | 2022-11-02 | — | — | EP | disclosed |
| US-20110206613-A1 | METHOD AND APPLICATION OF UNSYMMETRICALLY meso-SUBSTITUTED PORPHYRINS AND CHLORINS FOR PDT | BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG (AT) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110206613-A1 | METHOD AND APPLICATION OF UNSYMMETRICALLY meso-SUBSTITUTED PORPHYRINS AND CHLORINS FOR PDT | PTDSS2, PTDSS1, DLST | ABCG2 903/4885TOP1 3107/4885CYCS 1985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.